Dried Factor 8 Fraction from BPL (Batch 8 CRV 22344) was approved for clinical use. The product label noted that: "less than 7500 plasma donations used in the preparation of this batch". Read more about Dried Factor 8 Fraction from BPL (Batch 8 CRV 22344) was approved for clinical use. The product label noted that: "less than 7500 plasma donations used in the preparation of this batch".
BPL Factor 8 concentrate (Batch 1237) was approved for clinical use. The product label noted that: "less than 1500 plasma donations used in the preparation of this batch". Read more about BPL Factor 8 concentrate (Batch 1237) was approved for clinical use. The product label noted that: "less than 1500 plasma donations used in the preparation of this batch".
BPL Factor 8 concentrate (Batch 1227), approved for clinical use on 29 September 1976, had a product label which noted that: "less than 1500 plasma donations used in the preparation of this batch". Read more about BPL Factor 8 concentrate (Batch 1227), approved for clinical use on 29 September 1976, had a product label which noted that: "less than 1500 plasma donations used in the preparation of this batch".
In his written statement, Dr Foster said that a reduction in pool size around the early 1980s would have led to "an increase in importation of USA-donor derived Factor VIII concentrate which, in my opinion, carried a greater risk of HIV infection." Read more about In his written statement, Dr Foster said that a reduction in pool size around the early 1980s would have led to "an increase in importation of USA-donor derived Factor VIII concentrate which, in my opinion, carried a greater risk of HIV infection."
At the National Institute for Biological Standards and Control meeting, the minutes recorded that there "was much discussion about the optimal size of plasma pools, but no agreement that reduction of pool size would be either a practicable or a successful way to reduce the transmission of either hepatitis or AIDS". Read more about At the National Institute for Biological Standards and Control meeting, the minutes recorded that there "was much discussion about the optimal size of plasma pools, but no agreement that reduction of pool size would be either a practicable or a successful way to reduce the transmission of either hepatitis or AIDS".
A memo from Marietta Carr to members of the Alpha Operations Committee noted the discussion at a National Institute for Biological Standards and Control meeting where it was suggested that "the 100% incidence of non-A, non-B hepatitis is recent and is related to increased pool size since 1978." Read more about A memo from Marietta Carr to members of the Alpha Operations Committee noted the discussion at a National Institute for Biological Standards and Control meeting where it was suggested that "the 100% incidence of non-A, non-B hepatitis is recent and is related to increased pool size since 1978."
Dr Colvin, Dr Craske and others conducted a study titled, "A prospective study of cryoprecipitate administration: absence of evidence of virus infection". A small cohort of patients were treated only with cryoprecipitate between October 1982 and July 1984 and none developed hepatitis. Read more about Dr Colvin, Dr Craske and others conducted a study titled, "A prospective study of cryoprecipitate administration: absence of evidence of virus infection". A small cohort of patients were treated only with cryoprecipitate between October 1982 and July 1984 and none developed hepatitis.
Dr Rollag and others conducted the study which showed that people with bleeding disorders treated with factor products from "a relatively small and stable pool of domestic, non-paid donors" and the overall proportion with Hepatitis C was 41%, and for those with severe Haemophilia A or B it was 64% or 67%, respectively. Read more about Dr Rollag and others conducted the study which showed that people with bleeding disorders treated with factor products from "a relatively small and stable pool of domestic, non-paid donors" and the overall proportion with Hepatitis C was 41%, and for those with severe Haemophilia A or B it was 64% or 67%, respectively.
Dr Fletcher, Dr Craske, Dr Rizza and others wrote "Non-A non-B hepatitis after transfusion of factor VIII in infrequently treated patients" published in The British Medical Journal in 1983. The study suggested there was a difference in infectivity of factor concentrates when pool sizes were smaller. Read more about Dr Fletcher, Dr Craske, Dr Rizza and others wrote "Non-A non-B hepatitis after transfusion of factor VIII in infrequently treated patients" published in The British Medical Journal in 1983. The study suggested there was a difference in infectivity of factor concentrates when pool sizes were smaller.
Dr Kernoff and others published "High risk of non-A non-B hepatitis after a first exposure to volunteer or commercial clotting factor concentrates: effects of prophylactic immune serum globulin". It showed there was a near 100% risk of hepatitis for first treatment with factor concentrates and that NHS concentrates were little better. The study followed patients between 1978-1983 when pool sizes used in the NHS were growing exponentially. Read more about Dr Kernoff and others published "High risk of non-A non-B hepatitis after a first exposure to volunteer or commercial clotting factor concentrates: effects of prophylactic immune serum globulin". It showed there was a near 100% risk of hepatitis for first treatment with factor concentrates and that NHS concentrates were little better. The study followed patients between 1978-1983 when pool sizes used in the NHS were growing exponentially.